Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Melanoma 101Carcinoma, Non-Small-Cell Lung 88Carcinoma, Renal Cell 54Neoplasm Metastasis 37Squamous Cell Carcinoma of Head and Neck 32Colorectal Neoplasms 32Carcinoma, Hepatocellular 32Lung Neoplasms 31Hodgkin Disease 25Neoplasms 24Urinary Bladder Neoplasms 21Pancreatic Neoplasms 21Carcinoma, Transitional Cell 20Breast Neoplasms 19Stomach Neoplasms 17Brain Neoplasms 17Prostatic Neoplasms 16Small Cell Lung Carcinoma 15Sarcoma 15Multiple Myeloma 14Head and Neck Neoplasms 14Esophageal Neoplasms 14Glioblastoma 11Uterine Cervical Neoplasms 10Rectal Neoplasms 10Neuroendocrine Tumors 10Lymphoma 10Recurrence 9Ovarian Neoplasms 9Nasopharyngeal Carcinoma 9

Interventions

varlilumab 1Vincristine 1Tomography, X-Ray Computed 1Rituximab 1Prednisone 1Nivolumab 1Interferons 1Immunoglobulin G 1Etoposide 1Echocardiography 1EPOCH protocol 1Doxorubicin 1Disulfides 1Cyclophosphamide 1Caves 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphomatoid Granulomatosis × Nivolumab × Clear all
NCT03038672 2026-05-12

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2 Active not recruiting
54 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡